Current Understanding of Cancer-intrinsic PD-L1: Regulation of Expression and Its Protumoral Activity

Overview

Journal BMB Rep

Specialties Biochemistry
Molecular Biology

Date 2020 Dec 10

PMID 33298250

Citations 20

Authors

Pedram Yadollahi

You-Kyoung Jeon

Wooi Loon Ng

Inhak Choi

Affiliations

Soon will be listed here.

Abstract

In the last decade, we have witnessed an unprecedented clinical success in cancer immunotherapies targeting the programmed cell-death ligand 1 (PD-L1) and programmed cell-death 1 (PD-1) pathway. Besides the fact that PD-L1 plays a key role in immune regulation in tumor microenvironment, recently a plethora of reports has suggested a new perspective of non-immunological functions of PD-L1 in the regulation of cancer intrinsic activities including mesenchymal transition, glucose and lipid metabolism, stemness, and autophagy. Here we review the current understanding on the regulation of expression and intrinsic protumoral activity of cancer-intrinsic PD-L1. [BMB Reports 2021; 54(1): 12-20].

Citing Articles

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).

Angelicola S, Giunchi F, Ruzzi F, Frascino M, Pitzalis M, Scalambra L J Transl Med. 2025; 23(1):2.

PMID: 39748404 PMC: 11697469. DOI: 10.1186/s12967-024-06023-8.

Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice.

Song M, Cheng H, Zou H, Ma K, Lu L, Wei Q BMC Cancer. 2024; 24(1):673.

PMID: 38825709 PMC: 11145829. DOI: 10.1186/s12885-024-12407-2.

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.

Tu S, Trikannad A, Vellanki S, Hussain M, Malik N, Singh S Cancers (Basel). 2024; 16(6).

PMID: 38539487 PMC: 10969562. DOI: 10.3390/cancers16061151.

Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.

Usta S, Uchihashi T, Kodama S, Kurioka K, Inubushi T, Shimooka T Int J Mol Sci. 2023; 24(24).

PMID: 38139110 PMC: 10743423. DOI: 10.3390/ijms242417282.

The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1.

Erlichman N, Meshel T, Baram T, Abu Raiya A, Horvitz T, Ben-Yaakov H Cells. 2023; 12(19).

PMID: 37830552 PMC: 10571791. DOI: 10.3390/cells12192338.

References

Dorand R, Nthale J, Myers J, Barkauskas D, Avril S, Chirieleison S . Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016; 353(6297):399-403. PMC: 5051664. DOI: 10.1126/science.aae0477. View

Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C . Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020; 10(1):2083. PMC: 7005709. DOI: 10.1038/s41598-020-58674-4. View

Janse van Rensburg H, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P . The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. Cancer Res. 2018; 78(6):1457-1470. DOI: 10.1158/0008-5472.CAN-17-3139. View

Almozyan S, Colak D, Mansour F, Alaiya A, Al-Harazi O, Qattan A . PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation. Int J Cancer. 2017; 141(7):1402-1412. PMC: 5575465. DOI: 10.1002/ijc.30834. View

Lim S, Li C, Xia W, Cha J, Chan L, Wu Y . Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016; 30(6):925-939. PMC: 5171205. DOI: 10.1016/j.ccell.2016.10.010. View

Kim S, Jang J, Koh J, Kwon D, Kim Y, Paeng J . Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. J Exp Clin Cancer Res. 2019; 38(1):462. PMC: 6852926. DOI: 10.1186/s13046-019-1407-5. View

Li C, Lim S, Xia W, Lee H, Chan L, Kuo C . Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016; 7:12632. PMC: 5013604. DOI: 10.1038/ncomms12632. View

Zhang Y, Zeng Y, Liu T, Du W, Zhu J, Liu Z . The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res. 2019; 20(1):164. PMC: 6647099. DOI: 10.1186/s12931-019-1137-4. View

Cai J, Wang D, Zhang G, Guo X . The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. Onco Targets Ther. 2019; 12:8437-8445. PMC: 6800566. DOI: 10.2147/OTT.S221340. View

10.

Xu Y, Lv L, Liu Y, Smith M, Li W, Tan X . Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest. 2019; 129(10):4316-4331. PMC: 6763236. DOI: 10.1172/JCI129317. View

11.

Gato-Canas M, Zuazo M, Arasanz H, Ibanez-Vea M, Lorenzo L, Fernandez-Hinojal G . PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Rep. 2017; 20(8):1818-1829. DOI: 10.1016/j.celrep.2017.07.075. View

12.

Green M, Rodig S, Juszczynski P, Ouyang J, Sinha P, ODonnell E . Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18(6):1611-8. PMC: 3321508. DOI: 10.1158/1078-0432.CCR-11-1942. View

13.

Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y . Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway. Oncogene. 2018; 37(30):4164-4180. DOI: 10.1038/s41388-018-0252-x. View

14.

Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z . LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020; 53(9):e12855. PMC: 7507373. DOI: 10.1111/cpr.12855. View

15.

Zhao L, Liu Y, Zhang J, Liu Y, Qi Q . LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019; 10(10):731. PMC: 6769008. DOI: 10.1038/s41419-019-1886-5. View

16.

Wei S, Wang K, Huang X, Zhao Z, Zhao Z . LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019; 33:2058738419859699. PMC: 6595645. DOI: 10.1177/2058738419859699. View

17.

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

18.

Xu J, Meng Q, Li X, Yang H, Xu J, Gao N . Long Noncoding RNA MIR17HG Promotes Colorectal Cancer Progression via miR-17-5p. Cancer Res. 2019; 79(19):4882-4895. DOI: 10.1158/0008-5472.CAN-18-3880. View

19.

Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S . Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology. 2016; 5(3):e1094598. PMC: 4839382. DOI: 10.1080/2162402X.2015.1094598. View

20.

Zhang X, Li F, Zheng Y, Wang X, Wang K, Yu Y . Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog . Oxid Med Cell Longev. 2019; 2019:9078209. PMC: 6393877. DOI: 10.1155/2019/9078209. View